Significance of ABC transporter in predicting response and adverse effect of chemotherapy for esophageal cancer

• Project/Area Number: 15K19888
• Research Category: Grant-in-Aid for Young Scientists (B)
• Allocation Type: Multi-year Fund
• Research Field: Digestive surgery
• Research Institution: Osaka University
• Principal Investigator: Tomoki Makino 大阪大学, 医学系研究科, 助教 (80528620)
• Project Period (FY): 2015-04-01 – 2017-03-31
• Project Status: Completed (Fiscal Year 2016)
• Budget Amount: ¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000); Fiscal Year 2016: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000); Fiscal Year 2015: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
• Keywords: ABCトランスポーター / 食道癌 / 化学療法 / 副作用 / MRP2

Outline of Final Research Achievements

Expression of ABCC2 (one of ABC transporters), assessed by quantitative RT-PCR and immunohistochemistry (IHC), was found to be increased in esophageal cancer with vs without preoperative chemotherapy, and non-responders vs responders to preoperative chemotherapy. In resected specimen, cases with high ABCC2 expression showed more favorable survival compared ones with low ABCC2 expression. In a panel of esophageal cancer cell lines (TE1,5,6,9,10,11,14,15), high ABCC2 expression was significantly associated resistance to chemotherapy, in particular cisplatin. However no apparent relation was identified between ABCC2 expression and adverse effect of chemotherapy.